-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On December 1, Buchang Pharmaceutical issued an announcement stating that its wholly-owned subsidiary Luzhou Buchang’s "recombinant human parathyroid hormone (1-84) for injection" clinical trial application was recently accepted by the National Medical Products Administration.
Luzhou Buchang obtained the clinical trial of recombinant human parathyroid hormone (1-84) for injection this time.
The proposed indications of recombinant human parathyroid hormone (1-84) for injection include: 1.
Hypoparathyroidism is a group of clinical syndromes caused by undersecretion of parathyroid hormone (PTH) and/or insufficient effect
At present, the globally marketed similar drug is Takeda's Natpara®, which was approved for marketing by the US FDA in 2015